Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

NICE Doubtful On Cost-Effectiveness Of Tarceva

Related Content

NICE, In Final Decision, Rejects Roche's Tarceva For Lung Cancer Maintenance

Jun 29 2011

Related Companies

Roche Holding AG

AstraZeneca PLC

Additional Topics

United Kingdom Europe Cost Effectiveness Government Payers BioPharmaceutical

More from United Kingdom

More from Europe

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window